Strong deals are often passed not because the fundamentals fail, but because timing, structure and context quietly reshape how risk is perceived at the moment of decision.
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
